Azenta Gestione

Gestione criteri di controllo 0/4

Azenta Il CEO è John P. Marotta, nominato in Sep2024, ha un mandato di meno di un anno. possiede direttamente 0.031% delle azioni della società, per un valore di $ 658.00K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 0.8 anni.

Informazioni chiave

John P. Marotta

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.03%
Durata media del management	1.8yrs
Durata media del Consiglio di amministrazione	less than a year

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

John P. Marotta (43 yo)

less than a year

Mandato

Mr. John P. Marotta is President & CEO of Azenta, Inc. from September 9, 2024. Mr. Marotta serves as Executive in Residence at Patient Square Capital, LP since joining the firm in March 16, 2023. He levera...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jason Joseph	Senior VP	13.7yrs	US$1.44m	0.25% $ 5.3m
John P. Marotta	President & CEO	less than a year	Nessun dato	0.031% $ 658.0k
Lawrence Lin	Executive VP & CFO	no data	Nessun dato	Nessun dato
Violetta Hughes	VP & Chief Accounting Officer	1.3yrs	Nessun dato	0.00065% $ 14.0k
Michael Paulo	VP and Chief Information & Digital Officer	7.3yrs	Nessun dato	Nessun dato
Yvonne Perron	Vice President of Financial Planning & Analysis and Investor Relations	no data	Nessun dato	Nessun dato
John O'Brien	Senior Vice President of Corporate Development	14.5yrs	Nessun dato	Nessun dato
Olga Pirogova	Senior VP & Chief HR Officer	1.3yrs	Nessun dato	0.0011% $ 24.5k
J. Woodward	Senior Vice President of Global Quality & Regulatory	15yrs	Nessun dato	Nessun dato
Ginger Zhou	Senior VP and GM of the Genewiz Multiomics & Synthesis Solutions	5.5yrs	Nessun dato	0.021% $ 459.2k
David Wang	Senior VP & GM of Sample Management Solutions	1.8yrs	Nessun dato	0.013% $ 285.1k
Herman Cueto	Employee Advisor	no data	Nessun dato	0.0092% $ 197.1k

1.8yrs

Durata media

50yo

Età media

Gestione esperta: Il team dirigenziale di 0HQ1 non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Tina Nova	Independent Director	1.8yrs	US$207.50k	0.013% $ 286.0k
Michael Rosenblatt	Independent Director	6.2yrs	US$260.00k	0.029% $ 614.4k
Martin Madaus	Independent Director	less than a year	Nessun dato	0.016% $ 348.9k
Didier Hirsch	Independent Director	less than a year	Nessun dato	0.0076% $ 163.2k
Alan Malus	Independent Director	no data	Nessun dato	0.0022% $ 46.8k
Edward Bousa	Independent Director	less than a year	Nessun dato	0.0054% $ 116.1k
Robyn Davis	Independent Vice Chair of the Board	11.4yrs	US$278.75k	0.065% $ 1.4m
William Cornog	Independent Director	no data	Nessun dato	0.032% $ 695.1k
Erica McLaughlin	Independent Director	4.6yrs	US$273.75k	0.028% $ 603.9k
Frank Casal	Independent Chairman	3yrs	US$275.00k	0.021% $ 442.5k
Quentin Koffey	Independent Director	no data	Nessun dato	0.0022% $ 46.8k

0.8yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 0HQ1 non è considerato esperto (durata media del mandato 0.8 anni), il che suggerisce un nuovo consiglio.

Azenta Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Independent Director recently bought US$495k worth of stock

Azenta, Inc. Announces Chief Financial Officer Changes

Azenta, Inc. Announces Management Changes

Stephen Schwartz to Retire as CEO of Azenta, Inc

High number of new directors

High number of new directors

Recent updates

Azenta, Inc.(NasdaqGS:AZTA) dropped from S&P 400 Health Care (Sector)

Independent Director recently bought US$495k worth of stock

Full year 2024 earnings released: US$3.09 loss per share (vs US$0.19 loss in FY 2023)

Azenta, Inc. Announces Chief Financial Officer Changes

Azenta, Inc. to Report Q4, 2024 Results on Nov 12, 2024

Azenta, Inc Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test

Azenta, Inc. Announces Management Changes

Forecast to breakeven in 2026

No longer forecast to breakeven

New minor risk - Share price stability

Azenta, Inc. to Report Q3, 2024 Results on Aug 06, 2024

Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024

Second quarter 2024 earnings released: US$2.47 loss per share (vs US$0.029 loss in 2Q 2023)

Stephen Schwartz to Retire as CEO of Azenta, Inc

Azenta, Inc. to Report Q2, 2024 Results on May 08, 2024

Now 21% overvalued

High number of new directors

Now 20% overvalued

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.15 loss in 1Q 2023)

High number of new directors

Azenta, Inc. Announces the Launch of the BioArc Ultra

Azenta, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc

Azenta, Inc., Annual General Meeting, Jan 30, 2024

Azenta, Inc. Provides Earnings Guidance for the Full Year Fiscal 2024

Full year 2023 earnings released: US$0.19 loss per share (vs US$0.15 loss in FY 2022)

Azenta, Inc. to Report Q4, 2023 Results on Nov 13, 2023

Politan Capital Provides Information to the Shareholders

Azenta, Inc. Announces Chief Financial Officer Changes, Effective October 16, 2023

Azenta, Inc. Announces Executive Vice President Changes, Effective October 16, 2023

Politan Capital Management Engages in Discussions with Azenta

Politan Capital Management Engages in Discussions with Azenta

New minor risk - Insider selling

Insider recently sold US$407k worth of stock

Third quarter 2023 earnings released: US$0.039 loss per share (vs US$0.094 loss in 3Q 2022)

Azenta, Inc. Revises Revenue Guidance for the Full Year of 2023

Azenta, Inc. to Report Q3, 2023 Results on Aug 08, 2023

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: US$0.029 loss per share (vs US$0.024 loss in 2Q 2022)

Azenta, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q2, 2023 Results on May 09, 2023

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.038 profit in 1Q 2022)

Azenta, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q1, 2023 Results on Feb 08, 2023

Azenta, Inc. (NasdaqGS:AZTA) acquired Ziath Ltd.

Azenta, Inc. Announces Election of Directors

Azenta, Inc., Annual General Meeting, Jan 31, 2023

Full year 2022 earnings released: US$0.15 loss per share (vs US$0.39 loss in FY 2021)

Azenta Announces Board Resignations

Azenta, Inc. to Report Q4, 2022 Results on Nov 14, 2022

Azenta, Inc. Announces Matthew McManus Would No Longer Serve as the Companys Chief Operating Officer Effective as of October 14, 2022

Azenta, Inc. (NasdaqGS:AZTA) acquired B Medical Systems S.à R.L. from Navis Capital Partners.

Executive VP & COO recently bought US$502k worth of stock

Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.53 profit in 3Q 2021)

Azenta, Inc. Provides Earnings Guidance for the Fourth Quarter Fiscal 2022

Azenta, Inc. (NasdaqGS:AZTA) entered into an agreement to acquire B Medical Systems S.à R.L. for approximately €460 million.

Azenta, Inc. Provides Earnings Guidance for the Third Fiscal Quarter Ended June 30, 2022

Azenta, Inc.(NasdaqGS:AZTA) dropped from Russell 3000E Growth Index

Azenta, Inc. announced delayed 10-Q filing

Second quarter 2022 earnings released: US$0.024 loss per share (vs US$0.32 profit in 2Q 2021)

Azenta, Inc. Provides Revenue Guidance for the Third Quarter of 2022

Azenta, Inc. to Report Q2, 2022 Results on May 03, 2022

Forecast breakeven date moved forward to 2022

Azenta, Inc. Provides Earnings Guidance for the Second Quarter Fiscal Year 2022

Azenta, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2023

Azenta, Inc.(NasdaqGS:AZTA) dropped from NASDAQ Composite Index